��ΰ��ơ��ͬ��߼��Ƽ��ڷ�Сϸ��ΰ��İ�ȫ�ԱȽ�

2019-12-26 14:56:35��

1.��߼��Ƽ�

��߼��Ƽ��һ��ͨ��ǿ��ϵͳ��˰�֢��Ʒ��ҩ��Ҫ��Ϊ��֣�PD-1��PD-L1��Ƽ��

PD-1��һ��λ��ϵͳTϸ��ĵ�� (programmed cell death protein 1)��“��”��

PD-L1��һ�ִ��ڰ�ϸ��ĵ�� (programmed death-ligand 1)��“��”��

��PD-L1��PD-1��ϣ�Tϸ��ñ��ܵ��ƣ��ϸ��Բ��ܿص��

��ˣ�ֻҪ��ֹPD-1��PD-L1�Ӵ��һ��ǽ�ϣ��ϵͳ��Լ��Ч��PD-1��PD-L1��Ƽ��͸��ԭ��Ѿ�Ӧ��ڲ�ͬ��֢�ϣ��Сϸ��ΰ��

2.��ȫ�Ե��о��Ա�

��о��֤��Щ��Ƶ��޽�չ�ķ�Сϸ��ΰ��ߣ��߼��Ƽ��Ϊ��Ч��ƣ��ֳ��õİ�ȫ�ԡ�

��Щҩ��PD-1��Ƽ��䵥�� (Nivolumab) ��ķ�� (Pembrolizumab)��Լ�PD-L1��Ƽ��쵥�� (Atezolizumab)��ȴ�ͳ��Ƹ��ʤ��ӳ��ںͼ��˸��á�

��о��ʾ��Ϊһ��ƣ��ķ��Ч��ɢ�ķ�Сϸ��ΰ��ı��Ի��Ϊ��ߵ��ģʽ��

��Щ��߼��Ƽ��ĸ��㷺Ӧ�ã�һ��о��Աͨ��Ѽ��ҽѧ��ۺϷ��̽��Ƽ� (PD-1/PD-L1) ��Ʒ�Сϸ��ΰ��İ�ȫ�ԡ�

�о��Ա��2000��2016��ҽѧ��Ѱ��й��߼��Ƽ�Ӧ��ڷ�Сϸ��ΰ��о��23��ס�PD-1��Ƽ��ʮ�� (��3,284��)��PD-L1��Ƽ��µ�11�� (��2,460��)��

��ݷ��ʾ��黼�ߵĻ��(��䡢��ʷ��) ���ࡣ��ԣ��ӽ��ɻ��߶��߼��Ƽ��з�Ӧ��

ҩ�ﰲȫ�Է��棬��PD-1��Ƽ��ƵĻ��ߣ��64%��ʾ�и��ã��PD-L1��Ƽ��ƵĻ��(66%)��黼��У�ƣ����ĸ�� (��ռԼ20%)��

��ڴ��ؼ��ĸ��(��弶)��PD-L1��Ƽ��ı��ʽ�PD-1��Ƽ�һ��Խϸ� (�ֱ�Ϊ21%��13%)��ϵͳ��صĸ��÷��棬��PD-1��Ƽ�һ��Ϊ�� (16%��11%)��ձ�Ϊ��״�ٹ��ܼ��ˡ�

�Ӹ��ҩ��ȷ�³�� (Durvalumab) �ĸ��ñ��߼��Ƽ��϶� (��75%�Ļ��)��Ϊ��ķ��(Pembrolizumab) �Ͱ�ά�� (Avelumab) (�ֱ��67.5%��67%�Ļ��)��

��ۺϷ��ʹ��˴��ݼ��5,744��PD-1/PD-L1��Ƽ��Ƶķ�Сϸ��ΰ��ߡ��о��Ա��֪��Ϊֹ�״ζ��߼��Ƽ��Щ��ߵİ�ȫ��PD-1��Ƽ��PD-L1��Ƽ��Ƿ��ͬ��塣

��֮��о��Ҫ��ŷ��ң��δ�ؿɷ�ӳ��޵�ʵ��Ȼ��ۺϽ��ʾ��಻ͬ��߼��Ƽ��Ч�Ͱ�ȫ��и��ͬ�ĵط��Щ��ҽ��ҽ��Ա��˽��Ʒ��Ϊ��ѡȡ��ʵ��ơ�

��

��ϲ��

��Ƽ�

��ͼƬ

��

���ΰ����ơ���ͬ���߼������Ƽ��ڷ�Сϸ���ΰ��İ�ȫ�ԱȽ�